A retrospective study on the outcomes of MPO-ANCA-associated vasculitis in dialysis-dependent patients

References

• Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014;16(2):R101.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Tani Y, Kimura H, Tanaka K, Hayashi Y, Asahi K, et al. Clinical outcomes of Japanese MPO-ANCA-related nephritis: significance of initial renal death for survival. Intern Med. 2012; 51(15):1969–76.
   PubMed Web of Science ®Google Scholar
• Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant. 2004;19(6):1403–11.
   PubMed Web of Science ®Google Scholar
• Lionaki S, Hogan SL, Jennette CE, Hu Y, Hamra JB, Jennette JC, et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009;76(6):644–51.
   PubMed Web of Science ®Google Scholar
• Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–7.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–32.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events v 4.0 (CTCAE). Available at http://evs.nci.nih.gov/ftp1/CTCAE/. Accessed 16 June 2010.
   Google Scholar
• Haubitz M, Koch KM, Brunkhorst R. Survival and vasculitis activity in patients with end-stage renal disease due to Wegener's granulomatosis. Nephrol Dial Transplant. 1998;13(7):1713–8.
   PubMed Web of Science ®Google Scholar
• Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 1998;9(7):1258–63.
   PubMed Web of Science ®Google Scholar
• Weidanz F, Day CJ, Hewins P, Savage CO, Harper L. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis. 2007;50(1):36–46.
   PubMed Web of Science ®Google Scholar
• Merino JL, Galeano C, Espejo B, Rivera M, Fernández-Lucas M, Caldés S, et al. A retrospective study on outcome of microscopic polyangiitis in chronic renal replacement therapy. Nephrol Dial Transplant. 2011;26(4):1360–6.
   PubMed Web of Science ®Google Scholar
• Tang W, Bose B, McDonald SP, Hawley CM, Badve SV, Boudville N, et al. The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New Zealand. Clin J Am Soc Nephrol. 2013;8(5):773–80.
   PubMed Web of Science ®Google Scholar
• Romeu M, Couchoud C, Delarozière JC, Burtey S, Chiche L, Harlé JR, et al. Survival of patients with ANCA-associated vasculitis on chronic dialysis: data from the French REIN registry from 2002 to 2011. QJM. 2014;107(7):545–55.
   PubMed Web of Science ®Google Scholar
• Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial. 2012;16(6):483–521.
   PubMed Web of Science ®Google Scholar
• McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012; 7(2):240–7.
   PubMed Web of Science ®Google Scholar
• Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64(2):542–8.
   PubMed Web of Science ®Google Scholar
• Itabashi M, Takei T, Morito T, Yabuki Y, Suzuki H, Ando M, et al. Estimation of BVAS in patients with microscopic polyangiitis in Japan. Clin Rheumatol. 2011;30(11):1499–505.
   PubMed Web of Science ®Google Scholar
• Befort P, Corne P, Filleron T, Jung B, Bengler C, Jonquet O, Klouche K. Prognosis and ICU outcome of systemic vasculitis. BMC Anesthesiol. 2013;13(1):27.
   PubMed Web of Science ®Google Scholar
• Yamagata K, Usui J, Saito C, Yamaguchi N, Hirayama K, Mase K, et al. ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes. Clin Exp Nephrol. 2012;16(4):580–8.
   PubMed Web of Science ®Google Scholar
• Ntatsaki E, Carruthers D, Chakravarty K, D’Cruz D, Harper L, Jayne D, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306–9.
   PubMed Web of Science ®Google Scholar
• Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Natchman PH. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005;143(9):621–31.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, Natchman PH. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58(9):2908–18.
   PubMed Web of Science ®Google Scholar
• Hassan TM, Hassan AS, Igoe A, Logan M, Gunaratnam C, McElvaney N, O’Neill SJ. Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow-up in ANCA-associated vasculitis. BMC Immunol. 2014;15(1):20.
   PubMed Web of Science ®Google Scholar